Starling Oncology, Inc. Stock Issued During Period, Value, Acquisitions
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Starling Oncology, Inc. stock issued during period, value, acquisitions for fiscal 2021 was $16.35M.
| Period end | Stock Issued During Period, Value, Acquisitions 3 month | Stock Issued During Period, Value, Acquisitions 12 month |
|---|---|---|
| 2021-12-31 | $16.35M 10-K · filed 2023-03-16 |